Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia

Rebeqa Gunnarsson1,5✉, Minjun Yang1,5, Andrea Biloglavit1, Vladimir Lazarevic6,2,3, Kajsa Paulsson1 and Bertil Johansson1,4

© The Author(s) 2022

Leukemia (2022) 36:1681–1684; https://doi.org/10.1038/s41375-022-01552-x

TO THE EDITOR

Single base substitutions (SBSs) and insertions/deletions (indels; IDs) arise through several mechanisms such as errors during DNA replication/repair and exposures to mutagens, with the different mutational processes occasionally generating specific mutational signatures. SBS signatures (SBSsigns) result from recurring trinucleotide patterns of the transition/transversion types of somatic single nucleotide variants (SNVs) and their flanking nucleotides, whereas ID signatures (IDsigns) are defined according to size, nucleotides affected, and the presence of repetitive/microhomology regions (https://cancer.sanger.ac.uk/signatures/).

Some signatures are associated with underlying etiologic factors, e.g. SBS7 and ID13 in UV-associated melanoma and SBS4 and ID3 in smoking-induced lung cancer [1, 2], whereas others are linked to inherent defects of DNA recombination, replication, and repair (SBS6 and ID1) or caused by spontaneous or enzymatic deamination (SBS1, SBS2, SBS3, SBS4, SBS5, SBS6 and ID1) or caused by spontaneous or enzymatic deamination (SBS1, SBS2, SBS3, SBS4, SBS5, SBS6 and ID1). Considering that SBS18 has been associated with DNA damage caused by reactive oxygen species (ROS) (https://cancer.sanger.ac.uk/signatures/sbs/sbs18/) and that the RUNX1::RUNX1T1 chimeric protein is known to downregulate the expression of the OGG1 gene encoding a DNA glycosylase that excises oxidized guanines [6], we hypothesized that ROS could be involved in the genesis of childhood AML with RUNX1::RUNX1T1 [3].

Whether SBS18 is overrepresented also in adult RUNX1::RUNX1T1-positive AML is unknown. In fact, our knowledge of SBSsigns is rudimentary—and non-existing as regards IDsigns—in adult core binding factor (CBF) AML, which consists of cases positive for either RUNX1::RUNX1T1 or CBF::MYH11 [inv(16) [p13q22]/t(16;16)[p13c22]] [7]. The only publication to date addressing SBSsigns in adult CBF AML reported a high frequency of SBS1 [8], a clock-like signature that accumulates with age (https://cancer.sanger.ac.uk/signatures/).

Published online: 1 April 2022
Received: 7 December 2021 Revised: 11 March 2022 Accepted: 17 March 2022

1Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. 2Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 3Stem Cell Centre, Lund University, Lund, Sweden. 4Department of Clinical Genetics and Pathology, Office for Medical Services, Region Skåne, Lund, Sweden. 5These authors contributed equally: Rebeqa Gunnarsson, Minjun Yang. ✉email: rebeqa.gunnarsson@med.lu.se

The average sequencing depths of the WGS varied from 29× to 57× per sample (median 40×) and the Q30 value was 96.23%, with 2 × 150 bp read length. The WGS analyses confirmed the RUNX1::RUNX1T1 and CBF::MYH11 gene fusions in all cases and also revealed that the genomic breaks clustered within introns 6 of RUNX1 and 1 of RUNX1T1 and within introns 5 of CBFB and 33 of MYH11, respectively (Supplementary Table 1). No other chimeric genes were detected. All chromosomal gains and losses previously found by conventional G-banding were identified by WGS except for two subclonal trisomies in one case (Supplementary Tables 1 and 2). WGS also identified 32 copy number abnormalities (≤10 Mb) and five uniparental isodisomies, all of which undetectable by chromosome banding analyses (Supplementary Table 2). None of the cases displayed any signs of chromothripsis.

A median of 1437 (range 22–1834) and 1049 (561–1369) SNVs was identified in the RUNX1::RUNX1T1- and CBF::MYH11-positive cases, respectively, corresponding to 0.01–0.61 SNVs/indels per Mb. Comparing the transition and transversion types between the two gene fusion groups revealed highly similar frequency distributions, except for a slight excess of C>T transitions in the cases with CBF::MYH11 (49% versus 47%; P = 0.012; Mann–Whitney U test; Supplementary Fig. 1). Overall, the most

LETTER OPEN

ACUTE MYELOID LEUKEMIA

Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia

Rebeqa Gunnarsson1,5✉, Minjun Yang1,5, Andrea Biloglavit1, Vladimir Lazarevic6,2,3, Kajsa Paulsson1 and Bertil Johansson1,4
common substitution types were, in decreasing order, C > T, T > C, C > A, T > A, C > G, and T > G (Supplementary Fig. 1). The frequencies of all these increased significantly with age (Supplementary Fig. 2), suggesting clock-like acquisitions [9]. The rainfall plot analysis revealed no evidence for any hypermutated (kataegic) regions in the CBF AMLs (data not shown). A median of 79 (range 9–115) and 55 (27–82) indels was detected in the RUNX1::RUNX1T1- and CBFB::MYH11-positive cases, respectively (0.003–0.038 indels per Mb). In total, 24,597 SNVs and indels were detected, of which 307 (1.2%) occurred in coding regions. Most of the recurrently mutated genes identified have previously been reported to harbor pathogenic SNVs and indels in CBF AML (Supplementary Table 3), e.g., ASXL2, KIT, KRAS, and ZBTB7A [8, 10].

To investigate the presence/frequencies of the different SBSsigns and IDsigns in the CBF AMLs, COSMIC v.3.2 (https://cancer.sanger.ac.uk/signatures/) was used. Among the top ten SBSsigns in the cases with RUNX1::RUNX1T1 or CBFB::MYH11, nine were present in both groups: SBS1 (the most common one), SBS5, SBS8, SBS18, SBS32, SBS37, SBS39, and SBS89, albeit with varying frequencies between the two fusion groups (Fig. 1). SBS5 has been associated with smoking in several cancer types, e.g., bladder cancer with ERCC2 mutations (https://cancer.sanger.ac.uk/signatures/sbs/sbs5). The smoking habits of the CBF AML patients were unknown, but none of the cases harbored variants in ERCC2 (Supplementary Table 3). SBS32 has been linked to prior therapy with azathioprine (https://cancer.sanger.ac.uk/signatures/sbs/sbs32/); however, no patient had received such treatment, indicating that mutational mechanisms other than exposure to azathioprine contribute to SBS32. SBS18 was also among the ten most common SBS signatures in both fusion groups: 1%-13% of the SBSs in eight of the ten cases with RUNX1::RUNX1T1 and in 2%-28% in 7/10 CBFB::MYH11-positive cases (Fig. 1). However, the relative contribution of SBS18 was significantly higher (18–28% in all cases) in pediatric RUNX1::RUNX1T1-positive cases in our previous study [3] (Supplementary Fig. 3). Among the top ten SBSsigns, one was unique for RUNX1::RUNX1T1 (SBS88) and one for CBFB::MYH11 (SBS16). Apart from SBS88, which has been linked to the genotoxic metabolite colibactin produced by E. coli and other enteric bacteria (https://cancer.sanger.ac.uk/signatures/sbs/sbs88/),

common substitution types were, in decreasing order, C > T, T > C, C > A, T > A, C > G, and T > G (Supplementary Fig. 1). The frequencies of all these increased significantly with age (Supplementary Fig. 2), suggesting clock-like acquisitions [9]. The rainfall plot analysis revealed no evidence for any hypermutated (kataegic) regions in the CBF AMLs (data not shown). A median of 79 (range 9–115) and 55 (27–82) indels was detected in the RUNX1::RUNX1T1- and CBFB::MYH11-positive cases, respectively (0.003–0.038 indels per Mb). In total, 24,597 SNVs and indels were detected, of which 307 (1.2%) occurred in coding regions. Most of the recurrently mutated genes identified have previously been reported to harbor pathogenic SNVs and indels in CBF AML (Supplementary Table 3), e.g., ASXL2, KIT, KRAS, and ZBTB7A [8, 10].

To investigate the presence/frequencies of the different SBSsigns and IDsigns in the CBF AMLs, COSMIC v.3.2 (https://cancer.sanger.ac.uk/signatures/) was used. Among the top ten SBSsigns in the cases with RUNX1::RUNX1T1 or CBFB::MYH11, nine were present in both groups: SBS1 (the most common one), SBS5, SBS8, SBS18, SBS32, SBS37, SBS39, and SBS89, albeit with varying frequencies between the two fusion groups (Fig. 1). SBS5 has been associated with smoking in several cancer types, e.g., bladder cancer with ERCC2 mutations (https://cancer.sanger.ac.uk/signatures/sbs/sbs5). The smoking habits of the CBF AML patients were unknown, but none of the cases harbored variants in ERCC2 (Supplementary Table 3). SBS32 has been linked to prior therapy with azathioprine (https://cancer.sanger.ac.uk/signatures/sbs/sbs32/); however, no patient had received such treatment, indicating that mutational mechanisms other than exposure to azathioprine contribute to SBS32. SBS18 was also among the ten most common SBS signatures in both fusion groups: 1%-13% of the SBSs in eight of the ten cases with RUNX1::RUNX1T1 and in 2%-28% in 7/10 CBFB::MYH11-positive cases (Fig. 1). However, the relative contribution of SBS18 was significantly higher (18–28% in all cases) in pediatric RUNX1::RUNX1T1-positive cases in our previous study [3] (Supplementary Fig. 3). Among the top ten SBSsigns, one was unique for RUNX1::RUNX1T1 (SBS88) and one for CBFB::MYH11 (SBS16). Apart from SBS88, which has been linked to the genotoxic metabolite colibactin produced by E. coli and other enteric bacteria (https://cancer.sanger.ac.uk/signatures/sbs/sbs88/),
the etiologies of the remaining top ten SBS signs are unknown. Six of the common SBS signs increased by age in a clock-like manner: SBS1, SBS5, SBS8, SBS19, SBS32, and SBS89 (Fig. 2). The five most common ID signs in the CBF AMLs were, in decreasing order, ID9, ID1, ID2, ID10, and ID5; the frequencies of these signatures did not differ significantly between RUNX1::RUNX1T1- and CBFB::MYH11-positive cases (Supplementary Fig. 4). ID9 has been correlated with mutations in TP53, genomic instability, and chromothripsis [11]. However, none of these features was present in our cases. ID1 and ID2 have been associated with slippage during DNA replication of the replicated (ID1) and template (ID2) strands (https://cancer.sanger.ac.uk/signatures/id/id1/, https://cancer.sanger.ac.uk/signatures/id/id2/), whereas the etiologies of ID5 and ID10 are unknown. In conclusion, our findings suggest that the etiologies/mechanisms underlying transitions/transversions, SBS signs, and ID signs are similar in the two CBF AML types (Fig. 1 and Supplementary Figs. 1 and 4). Unfortunately, the etiologies of many of the common SBS signs and ID signs in the RUNX1::RUNX1T1- and CBFB::MYH11-positive cases are presently unknown. However, those with known or suspected origins can be dichotomized into i) spontaneous DNA changes/errors (SBS1, ID1, and ID2) and ii)

Fig. 2 Absolute contributions of the most common single base substitution (SBS) signatures in adult core binding factor acute myeloid leukemia in relation to age. The RUNX1::RUNX1T1- and CBFB::MYH11-positive cases are shown in blue and red, respectively. The P values are based on linear regression analyses.
associations with external agents, gene mutations, and ROS (SBS5, SBS18, SBS32, SBS88, and ID9). The lower frequency of SBS18 in adult vs. pediatric AML, despite being among the most common SBS signs in the adult cases (Fig. 1 and Supplementary Fig. 3), may be explained by the fact that the SBS18 frequency did not increase with age in our patient cohort, whereas several other SBS signs did (Fig. 2). In a recent study of pediatric AML, SBS18 was related to intrinsic ROS mechanisms that may have been induced already during fetal development [5]. Thus, if SBS18 occurs early on during the leukemogenic process of CBF AML, it would be more pronounced in childhood than in adult cases because the latter would have accumulated other age-related SBS signs resulting in a relatively lower proportion of SBS18. Further studies of SBS18 and ROS-induced DNA damage in adult and childhood CBF AML are needed to clarify this issue.

DATA AVAILABILITY
The dataset generated during the current study will be made available in the EGA-SE depository upon its completion. Until then, the data are available from the corresponding author upon request through the following https://doi.org/10.17062/scilifelab.17082971 (WGS dataset).
Supplementary information is available at Leukemia’s website.

REFERENCES
1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7461):415–21.
2. Nakagawa H, Fujita M. Whole genome sequence analysis for cancer genetics and precision medicine. Cancer Sci. 2018;109(5):13–22.
3. Gunnarsson R, Yang M, Olsson-Arvidsson L, Biloglav A, Behrendtz M, Castor A, et al. Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing. Blood. 2021;135:1485–9.
4. Bru Ford EA, Antonescu CR, Carroll AJ, Chinnaiyan A, Cree IA, Cross NCP, et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021;35:3040–3.
5. Brandis MA, Bertrums EJM, van Roosmalen MJ, Hofman DA, Oka R, Verheul M, et al. Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes. Blood Cancer Disc. 2021;5:4849–99.
6. Forster VJ, Nahari MI, Martinez-Soria N, Bradburn AK, Ptasinska A, Assi SA, et al. The leukemia-associated RUNXI/ETO oncoprotein confers a mutator phenotype. Leukemia. 2016;30:250–3.
7. Marcucci G, Caliguri MA, Bloomfield CD. Molecular and clinical advances incore binding factor primary acute myeloid leukemia: a paradigm for translational research inmalignant hematol. Cancer Invest. 2000;18:768–80.
8. Faber ZJ, Chen X, Larson Gedman A, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551–6.
9. Zhang L, Dong X, Lee M, Maslov AY, Wang T, Vigg J. Single-cell whole-genome sequencing reveals the functional landscape of somatic mutations in B lymphocytes across the human lifespan. Proc Natl Acad Sci USA. 2019;116:9014–9.
10. Jahn N, Terzer T, Sträng E, Dolnik A, Cociardi S, Panina E, et al. Genomic heterogeneity incore-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020;4:6342–52.
11. Thatikonda V, Islam SMA, Jones BC, Gröbner SN, Warsaw G, Hutter B, et al. Comprehensive analysis of mutational signatures in pediatric cancers. BioRxiv https://doi.org/10.1101/2021.09.28.462210.

ACKNOWLEDGEMENTS
This study was supported by grants from the Swedish Cancer Society (20 0792 PfJ), the Swedish Research Council (2020-01164), the Swedish Childhood Cancer Foundation (TJ2020-0024, PR2020-0033, and PR2018-0004), and Governmental Funding of Clinical Research within the National Health Service. Sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. This facility is part of the National Genomics Infrastructure (NGI) Sweden and Science for Life Laboratory. The SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. The computations were performed on resources provided by LUNARC through Lund University under Project LSENS 2018/3-4.

AUTHOR CONTRIBUTIONS
RG planned and performed research and wrote the paper. MV performed the bioinformatic analyses and wrote the paper. AB and KP performed research. VL provided patient samples and clinical data. BJ planned research and wrote the paper. The paper was reviewed and approved by all the authors.

FUNDING
The Swedish Cancer Society (20 0792 PfJ), the Swedish Research Council (2020-01164), the Swedish Childhood Cancer Foundation (TJ2020-0024, PR2020-0033, and PR2018-0004), and Governmental Funding of Clinical Research within the National Health Service. Open access funding provided by Lund University.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41375-022-01552-x.
Correspondence and requests for materials should be addressed to Rebeqa Gunnarsson.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022